Last reviewed · How we verify
Drug: Hyperacute Lung Cancer Cell Vaccine
Drug: Hyperacute Lung Cancer Cell Vaccine is a Biologic drug developed by NewLink Genetics Corporation. It is currently in Phase 1 development.
At a glance
| Generic name | Drug: Hyperacute Lung Cancer Cell Vaccine |
|---|---|
| Sponsor | NewLink Genetics Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Treatment for Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: Hyperacute Lung Cancer Cell Vaccine CI brief — competitive landscape report
- Drug: Hyperacute Lung Cancer Cell Vaccine updates RSS · CI watch RSS
- NewLink Genetics Corporation portfolio CI
Frequently asked questions about Drug: Hyperacute Lung Cancer Cell Vaccine
What is Drug: Hyperacute Lung Cancer Cell Vaccine?
Drug: Hyperacute Lung Cancer Cell Vaccine is a Biologic drug developed by NewLink Genetics Corporation.
Who makes Drug: Hyperacute Lung Cancer Cell Vaccine?
Drug: Hyperacute Lung Cancer Cell Vaccine is developed by NewLink Genetics Corporation (see full NewLink Genetics Corporation pipeline at /company/newlink-genetics-corporation).
What development phase is Drug: Hyperacute Lung Cancer Cell Vaccine in?
Drug: Hyperacute Lung Cancer Cell Vaccine is in Phase 1.